Study of HLX43 for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests an experimental drug called HLX43 for people with advanced pancreatic cancer that has not responded to at least one previous treatment. The goal is to see if HLX43 can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of pancreatic cancer called pancreatic ductal adenocarcinoma (PDAC) that has spread or cannot be removed with surgery.
- You must have tried at least one standard treatment (like chemotherapy) that did not work.
- You must be willing to provide a tumor tissue sample (from a past biopsy or a new one) for testing.
- You must be in generally good health, as measured by a performance status score of 0 to 2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This study tests a new drug called HLX43 for people whose breast cancer has continued to grow after hormone therapy. The goal is to see if HLX43 can help shrink or control the cancer.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.